Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ CXCR5 Recombinant Rabbit Monoclonal Antibody (9Q10I2)

Rabbit Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA542900

Catalog No. PIMA542900


Only null left
Add to Cart
This item is not returnable. View return policy

Description

Description

Positive test controls include: Jurkat, K-562, Mouse lung, Mouse spleen, Mouse thymus, Rat thymus. The target is usually found in the following locations: Cell membrane, Multi-pass membrane protein. Immunogen sequence: SPYHIVIFLD TLARLKAVDN TCKLNGSLPV AITMCEFLGL AHCCLNPMLY TFAGVKFRSD LSRLLTKLGC TGPASLCQLF PSWRRSSLSE SENATSLTTF.

CXCR5 (C-X-Chemokine Receptor Type 5, CD185) also known as Burkitt lymphoma receptor 1 (BLR1) belongs to the CXC chemokine receptor family. CXCR5 is a G protein-coupled seven transmembrane receptor for chemokine BLC. CXCR5 gene is specifically expressed in Burkitt's lymphoma and lymphatic tissues, such as follicles in lymph nodes, as well as in spleen. Studies of CXCR5 suggest that it plays an essential role in B cell migration. CXCR5 expression has been reported in human blood and salivary gland and in animal lymphatic organs, blood, bone marrow, brain, liver, lymph node, skin, spleen, stomach, and tonsil. ESTs (expressed sequence tags) have been isolated from human brain, germ cell, lung, lymph, and pancreas. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Research studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This turn-off activity in GPCRs have tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which are used in mental health and allergy applications, respectively.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CXCR5
Recombinant Monoclonal
0.4 mg/mL
PBS with 0.05% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3
P32302, P34997, Q04683
CXCR5
A synthetic peptide corresponding to a sequence within amino acids 273-372 of human CXCR5 (P32302).
100 μL
Primary
Human, Mouse, Rat
Antibody
IgG
ELISA, Western Blot, Immunocytochemistry
9Q10I2
Unconjugated
CXCR5
Blr1; Blr-1; Burkitt lymphoma receptor 1; burkitt lymphoma receptor 1 homolog; Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5); Burkitt lymphoma receptor 1, GTP-binding protein; C Cmotif chemokine; C X C motif chemokine; CC motif chemokine; CCmotif chemokine; CD185; CD185 antigen; chemochine (C-X-C motif) receptor 5; chemokine (C-X-C motif) receptor 5; CXC; C-X-C chemokine receptor type 5; CXC motif chemokine; C-X-C motif chemokine receptor 5; CXCR5; CXC-R5; CXCR-5; EGK_06966; Fusin; Gpcr6; GPR9; HUMSTR; LESTR; MDR15; MDR-15; Monocyte-derived receptor 15; neurolymphatic receptor; NLR
Rabbit
Affinity chromatography
RUO
12145, 29363, 643
-20°C, Avoid Freeze/Thaw Cycles
Liquid
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.